Torax's GERD device backed by FDA advisory panel
This article was originally published in Clinica
Executive Summary
Torax Medical's lead product, the LINX reflux management system, looks set to reach the US market after an FDA advisory panel voted in favour of its approval. Specifically, the panel recommended its use in patients with gastroesophageal reflux disease (GERD) who do not respond to medication, which includes the blockbuster proton pump inhibitor (PPI) drugs such as omeprazole, marketed by AstraZeneca as Losec and Prilosec.